HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Melanocortins protect against progression of Alzheimer's disease in triple-transgenic mice by targeting multiple pathophysiological pathways.

Abstract
Besides specific triggering causes, Alzheimer's disease (AD) involves pathophysiological pathways that are common to acute and chronic neurodegenerative disorders. Melanocortins induce neuroprotection in experimental acute neurodegenerative conditions, and low melanocortin levels have been found in occasional studies performed in AD-type dementia patients. Here we investigated the possible neuroprotective role of melanocortins in a chronic neurodegenerative disorder, AD, by using 12-week-old (at the start of the study) triple-transgenic (3xTg-AD) mice harboring human transgenes APPSwe, PS1M146V, and tauP301L. Treatment of 3xTg-AD mice, once daily until the end of the study (30 weeks of age), with the melanocortin analog [Nle(4),D-Phe(7)]-α-melanocyte-stimulating hormone (NDP-α-MSH) reduced cerebral cortex/hippocampus phosphorylation/level of all AD-related biomarkers investigated (mediators of amyloid/tau cascade, oxidative/nitrosative stress, inflammation, apoptosis), decreased neuronal loss, induced over-expression of the synaptic activity-dependent gene Zif268, and improved cognitive functions, relative to saline-treated 3xTg-AD mice. Pharmacological blockade of melanocortin MC4 receptors prevented all neuroprotective effects of NDP-α-MSH. Our study identifies, for the first time, a class of drugs, MC4 receptor-stimulating melanocortins, that are able to counteract the progression of experimental AD by targeting pathophysiological mechanisms up- and down-stream of β-amyloid and tau. These data could have important clinical implications.
AuthorsDaniela Giuliani, Alessandra Bitto, Maria Galantucci, Davide Zaffe, Alessandra Ottani, Natasha Irrera, Laura Neri, Gian Maria Cavallini, Domenica Altavilla, Annibale R Botticelli, Francesco Squadrito, Salvatore Guarini
JournalNeurobiology of aging (Neurobiol Aging) Vol. 35 Issue 3 Pg. 537-47 (Mar 2014) ISSN: 1558-1497 [Electronic] United States
PMID24094579 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Inc. All rights reserved.
Chemical References
  • Amyloid beta-Peptides
  • Melanocortins
  • Neuroprotective Agents
  • Receptor, Melanocortin, Type 4
  • tau Proteins
Topics
  • Alzheimer Disease (drug therapy, genetics)
  • Amyloid beta-Peptides (metabolism)
  • Animals
  • Apoptosis (genetics)
  • Disease Models, Animal
  • Disease Progression
  • Humans
  • Male
  • Melanocortins (pharmacology, therapeutic use)
  • Mice
  • Mice, Transgenic
  • Molecular Targeted Therapy
  • Neuroprotective Agents (pharmacology, therapeutic use)
  • Oxidative Stress (genetics)
  • Receptor, Melanocortin, Type 4 (physiology)
  • tau Proteins (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: